2017 Volume 57 Issue 2 Pages 81-87
The approval of nivolumab and pembrolizumab for advanced non-small cell lung cancer has allowed some patients to receive benefits such as prolonged overall survival and a long-term response with relatively mild adverse events. Meanwhile, there are patients who suffer from various disadvantages due to inappropriate patient selection, errors in evaluating treatment effects and high drug prices. We therefore need to evaluate the evidence and issues associated with nivolumab in order to better prepare any associated problems that need to be overcome in the future.
